Security key
26818M108
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 110,972,098
- Total 13F value
- $3,915,861,443
- Share change
- +15,560,726
- Put/Call ratio
- 30%
- SEC-reported price per share
- $35.29
- Number of holders
- 191
- Value change
- +$555,159,053
- Number of buys
- 122
- Number of sells
- 66
- Shares outstanding
- 164,426,217
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
191
Top holders
10
DYN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Dyne Therapeutics, Inc. SEC filings
Dyne Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 26818M108
Recent filing periods:
Ownership snapshot
Top reported holders of DYN - Dyne Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Atlas Venture Life Scienc...
Disclosed value leader
Atlas Venture Life Scienc...
Comparable rows
15/15
Latest evidence
31 Mar 2024
13F
Lead comparable stake: 4.9%
Showing 1-6 of 15 holder rows.
Quick read
Atlas Venture Life Science Advisors, LLC leads the comparable SEC ownership view at 4.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Atlas Venture Life Science Advisors, LLC's linked filing trail.
Comparable ownership
Top 5
Atlas Venture Life Science Adviso...
4.9%
FCPM III SERVICES B.V.
4.8%
BlackRock Finance, Inc.
3.3%
RA CAPITAL MANAGEMENT, L.P.
3%
Deep Track Capital, LP
2.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
4.9%
|
$227,691,661
8,020,136 shares
|
— | 31 Mar 2024 |
| FCPM III SERVICES B.V. |
13F
Company
|
4.8%
|
$222,729,884
7,845,364 shares
|
— | 31 Mar 2024 |
| BlackRock Finance, Inc. |
13F
Company
|
3.3%
|
$153,023,292
5,390,042 shares
|
— | 31 Mar 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
3%
|
$140,666,176
4,954,779 shares
|
— | 31 Mar 2024 |
| Deep Track Capital, LP |
13F
Company
|
2.8%
|
$129,327,323
4,555,383 shares
|
— | 31 Mar 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
2.6%
|
$120,778,896
4,254,276 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
191
Shares
110,972,098
Rows available
191
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
167
Q2 2024 holders
191
Holder diff
24
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend